Cowen analyst Ken Cacciatore raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $55.00 (from $35.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed OfferingSeptember 7, 2021 4:01 PM Impel NeuroPharma Inc. (IMPL) surges 59% as trading reumes on FDA approvalSeptember 3, 2021 9:18 AM Impel NeuroPharma Inc. (IMPL) Announces FDA Approval of TRUDHESA for MigraineSeptember 3, 2021 8:52 AM Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of MigraineSeptember 3, 2021 8:51 AM